Schizophrenia/Psychosis

The supposed “epidemic” of mental illness turns out to be mostly a myth in the US adult population, 2000-2015.

What an exciting time to be involved in understanding and providing care for people with schizophrenia spectrum disorders!

Psychiatrists who treat patients with psychosis in institutional, community, and crisis settings provide evaluations and medication management, but rarely consider psychotherapeutic interventions. However, such interventions can be critical in recovery.

Culture-the way people make meaning and live their lives in particular social worlds-matters in psychosis. The authors explore how a patient's cultural background should influence the way clinicians think about treatment and care.

The authors discuss the clinical implications of the changes in the DSM-5 section on schizophrenia spectrum and other psychotic disorders.

A review of the distinction between depressive and psychotic symptom domains, current knowledge about the etiology and neurobiology of depression and psychosis, and how this knowledge can inform the treatment of patients with features of both.

It’s not health care expenses that are driving up costs.

Are you aware of this newly identified risk factor for suicide?

This hormone-based therapy shows promise for older women with refractory symptoms.

The authors examine the literature on "quality of life" and how antipsychotics improve that for patients with schizophrenia.

What should you tell your patients with schizophrenia about exercise?

Art theory from the 20th century onward-despite the latter day efforts at denial-was nearly indistinguishable from psychoanalytic theory, and it parallels the philosophical struggles and pains that continue to plague psychiatry.

What should you do when patients with preexisting psychosis express an interest in lengthy travel?

Insights from the first study of mortality and cumulative psychotropic exposure in schizophrenia.

The authors parse myths and facts about decisional capacity, with the goal of preserving patients' dignity and autonomy and helping you mediate conflicts, meet bioethical challenges, and provide compassionate resolutions.

New insights from a large study that relied on objective biomarkers.

What is the risk of symptom recurrence after antipsychotic discontinuation in first-episode psychosis?

Proper technique, practiced over time, can transform an appointment from "medication management" to a serious change in behavior, as evidenced by the 5 examples featured in this article.

What role does DNA methylation play in schizophrenia?

Details of a randomized trial of an alpha-7 nicotinic receptor agonist in schizophrenia.

Methods of identifying and understanding the intricacies of psychosis in clinical settings.

For patients suffering the chronic, debilitating symptoms of schizophrenia, antipsychotic medication is a critical component of treatment-and may literally be life-saving.

How to make cognitive behavioral therapy for psychosis feasible in a busy practice with limited resources.

The key to identification of prodromal psychosis may lie in community-based outreach.

The personalized medicine approach is predicated upon a greater understanding of the biology of illness and how it plays out-uniquely and specifically-for each individual patient.

First-episode psychosis cases are presented here using the RAISE study model-individual sessions, family psycho-education, social advancement in school work, and an expert psychiatrist prescriber.

Is clozapine still the gold standard for treatment-resistant schizophrenia?

Do atypical antipsychotics increase the risk of major malformations among exposed infants?

Check out what's new in schizophrenia research, personality disorders, patient education, integrative psychiatry, addiction, and more.